Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CaPre (TM)
CaPre · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| CaPre | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| CaPre 1.0g | EXPERIMENTAL | - |
| CaPre 2.0g | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CaPre | DRUG | 4 x 1 g capsules administered orally once daily for 26 weeks |
| Placebo | DRUG | 4 x 1 g capsules administered orally once daily for 26 weeks |
| CaPre (TM) | DRUG | CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks. |
Inclusion Criteria: 1. Subjects ≥18 years of age. 2. Isolated hypertriglyceridemia, with triglycerides ≥500 mg/dL and \<1500 mg/dL (≥5.7 mmol/L and \<17.0 mmol/L) OR Mixed hyperlipidemia, with serum triglycerides ≥500 and \<1500 mg/dL treated with a statin, CAI or PCSK9I inhibitor, alone or in comb...
CaPre is being developed for the treatment of hypertriglyceridemia, a metabolic condition marked by elevated triglyceride levels. It is an investigational small molecule studied in adults 18 years and older. CaPre has not been approved for commercial use and remains in clinical development.
CaPre is being developed by Grace Therapeutics, Inc., which trades under the ticker GRCE. The company has sponsored the clinical program evaluating CaPre in hypertriglyceridemia, including the Phase 3 TRILOGY 1 and TRILOGY 2 studies and an earlier Phase 2 trial.
CaPre is in Phase 3 development for hypertriglyceridemia. Three trials have been completed: two Phase 3 studies, TRILOGY 1 and TRILOGY 2, and one Phase 2 study. No trials are currently active. CaPre is investigational and has not been approved by the FDA.
CaPre has been evaluated in three completed trials: NCT03398005 (TRILOGY 1), a Phase 3 study conducted in the United States; NCT03361501 (TRILOGY 2), a Phase 3 study run in the United States, Canada, and Mexico; and NCT01455844, a Phase 2 trial conducted in Canada. Total enrollment across these studies was 921 participants.
Yes, CaPre and CaPre (TM) refer to the same investigational drug candidate. CaPre (TM) is the trademarked form of the name used by Grace Therapeutics, Inc. for its small molecule being developed to treat hypertriglyceridemia.